Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage criteria
NEW YORK , Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary...
Conference Call and Webcast at 8:30 AM ET
Conference Call and Webcast at 8:30 AM ET
Veris Health progressed commercial expansion and advanced implantable physiological monitor development toward FDA submission
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement...
Conference Call and Webcast at 8:30 AM ET
Conference Call and Webcast at 8:30 AM ET
NEW YORK , April 24, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary...
NEW YORK , April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary...